Devang Mehta of Anand Rathi Makes A Packet From Suven Life Sciences. Check Out His Other Stock Picks As Well

Devang Mehta deserves to be complemented for his brilliant stock pick in Suven Life Sciences. The stock surged nearly 20% today. His other stock picks also appear to have high potential for gains

In his latest interview, Devang Mehta of Anand Rathi sent a no-holds-barred buy call on Suven Life Sciences. He pointed out that Suven is “an excellent high-growth, high-margin business” and it has “a superb balance sheet and good return ratios”. He added that Suven has a “huge monetisation opportunity for one of its molecules called SUVN-502”. Suven can be a “dark horse”, Devang said and projected a “conservative” price target of Rs 336 for the stock.

Well, today Suven surged nearly 20%, bringing joy to all those who had acted on Devang Mehta’s call.

It must also be noted that Suven Life Sciences is one of the seven stocks conferred with the privilege of being a “potential 100-bagger” stock by the Motilal Oswal 19th Wealth Creation Study Report.

We must also not forget to pay tribute to Vineeta Mahnot of Hem Securities who was one of the first spotters of the opportunity in Suven. Vineeta recommended a buy in November 2013 when the stock was available at a throwaway valuation of Rs. 46. Her followers are sitting on mind-boggling gains of 471%.

Coming back to Devang Mehta, he has also recommended a buy of Granules India and foreseen a target price of Rs. 1000 for the stock. His other stock picks include PTC Financial Services.

I am listing out here the fundamental features of a few well known stock advisory services. The fees charged, as well a few stocks that they are credited with having recommended, are set out. If you know of other service providers, do chip in. Also, if you have used any of these services and have […]

Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!